Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 4/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18373156 | 0.88 | NPY5R (0.45) | AVPR1ANPY5RSIGMAR1HTR2CPARP1 | |
| SCHEMBL31394077 | 0.83 | AVPR1A (0.51) | AVPR1ANPY5RSIGMAR1PARP1PARP10 | |
| SCHEMBL654562 | 0.82 | NPY5R (0.45) | AVPR1ANPY5RSIGMAR1HTR2CPARP1 | |
| SCHEMBL738397 | 0.82 | AVPR1A (0.50) | AVPR1ANPY5RSIGMAR1HTR2CPARP1 | |
| Hydrochloric Acid SCHEMBL6820620 | 0.81 | AVPR1A (0.49) | AVPR1ANPY5RSIGMAR1HTR2CPARP1 | |
| SCHEMBL31394738 | 0.80 | AVPR1A (0.47) | AVPR1ANPY5RSIGMAR1PARP1PARP10 | |
| SCHEMBL17586455 | 0.79 | OPRM1 (0.41) | AVPR1ANPY5RSIGMAR1HTR2CPARP1 | |
| SCHEMBL3839594 | 0.79 | AVPR1A (0.60) | AVPR1ANPY5RSIGMAR1DRD2 | |
| SCHEMBL171980 | 0.79 | SIGMAR1 (0.54) | AVPR1ANPY5RSIGMAR1 | |
| SCHEMBL29674557 | 0.79 | SIGMAR1 (0.54) | AVPR1ANPY5RSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066378-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-12162887-B2 | Spiro-oxazolones | HOFFMANN-LA ROCHE INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230106150-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2023-04-06 | — | — | US | disclosed |
| US-20200039997-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-10479796-B2 | Spiro-oxazolones | HOFFMAN-LA ROCHE INC. (US) | 2019-11-19 | — | — | US | disclosed |
| EP-3107916-B1 | SPIRO-OXAZOLONES | HOFFMANN LA ROCHE (CH) | 2019-03-20 | — | — | EP | disclosed |
| EP-3083633-B1 | SPIRO-OXAZOLONES | HOFFMANN LA ROCHE (CH) | 2017-11-29 | — | — | EP | disclosed |
| US-9828385-B2 | Spiro-oxazolones | HOFFMANN-LA ROCHE INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170008901-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2017-01-12 | — | — | US | disclosed |
| EP-3107916-A1 | SPIRO-OXAZOLONES | F. Hoffmann-La Roche AG (CH) | 2016-12-28 | — | — | EP | disclosed |
| US-20080146557-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS | BISSANTZ CATERINA | 2008-06-19 | — | — | US | disclosed |
| EP-1904477-A1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| US-7332501-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332501-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332501-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | US | disclosed |
| WO-2007006688-A1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006688-A1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | AVPR1A, AVPR2, AVPR1B | AVPR1A 1/4885NPY5R 200/4885SIGMAR1 44/4885 |
| US-12162887-B2 | Spiro-oxazolones | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885NPY5R 162/4885SIGMAR1 178/4885 |
| US-20250066378-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885NPY5R 162/4885SIGMAR1 178/4885 |
| US-20200039997-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885NPY5R 162/4885SIGMAR1 178/4885 |
| US-20170008901-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885NPY5R 162/4885SIGMAR1 178/4885 |
| US-20080146557-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS | AVPR1A, AVPR2, OXTR | AVPR1A 1/4885NPY5R 79/4885SIGMAR1 53/4885 |
| US-20230106150-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885NPY5R 162/4885SIGMAR1 178/4885 |
| US-10479796-B2 | Spiro-oxazolones | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885NPY5R 162/4885SIGMAR1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.